Cited by 169Lipoproteins and Cardiovascular HealthLipid metabolism and disordersPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.

Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

Keating, Gillian M, Croom, Katherine F·2007·Drugs

DOI 10.2165/00003495-200767010-00013

Open this paper in CoChat — free account

Abstract

Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures. Its lipid-modifying effects are mediated by activation of peroxisome proliferator-activated receptor-alpha. Fenofibrate also has nonlipid (i.e. pleiotropic) effects (e.g. it reduces fibrinogen, C-reactive protein and uric acid levels and improves flow-mediated dilatation). Fenofibrate improves lipid levels (in particular triglyceride [TG] and high-density lipoprotein-cholesterol [HDL-C] levels) in patients with primary dyslipidaemia. Its lipid-lowering profile means that fenofibrate is particularly well suited for use in atherogenic dyslipidaemia (characterised by high TG levels, low HDL-C levels and small, dense low-density lipoprotein [LDL] particles), which is commonly seen in patients with the metabolic syndrome and type 2 diabetes mellitus. Indeed, fenofibrate improves the components of atherogenic dyslipidaemia in patients with these conditions, including a shift from small, dense LDL particles to larger, more buoyant LDL particles. Greater improvements in lipid levels are seen when fenofibrate is administered in combination with an HMG-CoA reductase inhibitor (statin) or in combination with ezetimibe, compared with monotherapy with these agents. In the DAIS study, fenofibrate significantly slowed the angiographic progression of focal coronary atherosclerosis in patients with type 2 diabetes. In terms of clinical outcomes, although no significant reduction in the risk of coronary events was seen with fenofibrate in the FIELD trial in patients with type 2 diabetes, treatment was associated with a significantly reduced risk of total cardiovascular disease (CVD) events, primarily through the prevention of non-fatal myocardial infarction and coronary revascularisation. Subgroup analyses revealed significant reductions in total CVD events and coronary heart disease events in patients with no previous CVD, suggesting a potential role for primary prevention with fenofibrate in patients with early type 2 diabetes. Improvements were also seen in microvascular outcomes with fenofibrate in the FIELD trial. Fenofibrate is generally well tolerated, both as monotherapy and when administered in combination with a statin. Combination therapy with fenofibrate plus a statin appears to be associated with a low risk of rhabdomyolysis; no cases of rhabdomyolysis were reported in patients receiving such therapy in the FIELD trial. Thus, fenofibrate is a valuable lipid-lowering agent, particularly in patients with atherogenic dyslipidaemia.

Integrity signals

Registry

Crossref · 10.2165/00003495-200767010-00013

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global Prevalence of Diabetes
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
(1998) · PubMed · Cited by 4,290
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876
Diabetes and Atherosclerosis
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,765
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
Smith, S. C., Allen, J. K., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,102
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Increasing Prevalence of the Metabolic Syndrome Among U.S. Adults
Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2444 · Cited by 1,488
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Köenig, W., Habib, A., Merval, R., Lebret, M., Pineda‐Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,138
The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
Schoonjans, K., Staels, B., & Auwerx, J. H. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00066-5 · Cited by 1,045
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 849
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Steiner, G. A. (2001) · Cited by 732
Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
European guidelines on cardiovascular disease prevention in clinical practice<SBT>Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
Backer, G. D., Ambrosioni, E., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.02.013 · Cited by 508
Peroxisome proliterator-activated receptors, orphans with ligands and functions
Schoonjans, K., Martin, G. V., Staels, B., & Auwerx, J. H. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00006 · Cited by 488
Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study
Haffner, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2661 · Cited by 441
CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors
Chinetti, G., Gbaguidi, F. G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.-C., Tedgui, A., Najib-Fruchart, J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.20.2411 · Cited by 428
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
Vu‐Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J., Staels, B., & Auwerx, J. H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118118 · Cited by 403
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 322
Dyslipidemia Prevalence, Treatment, and Control in the Multi-Ethnic Study of Atherosclerosis (MESA)
Goff, D. C., Bertoni, A. G., Kramer, H., Bonds, D. E., Blumenthal, R. S., Tsai, M. Y., & Psaty, B. M. (2006) · Circulation · doi:10.1161/circulationaha.105.552737 · Cited by 315
Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
Grundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Tenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 307
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 294
Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells
Ylipaasto, P., Klingel, K., Lindberg, A., Otonkoski, T., Kandolf, R., Hovi, T., & Roivainen, M. (2004) · Diabetologia · doi:10.1007/s00125-003-1297-z · Cited by 294
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 282
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia
Athyros, V. G., Papageorgiou, A. A., Athyrou, V. V., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1198 · Cited by 259
ABC of arterial and venous disease: Vascular complications of diabetes
Donnelly, R. (2000) · BMJ · doi:10.1136/bmj.320.7241.1062 · Cited by 258
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J. H., Guillouzo, A., Fruchart, J., Rubin, E. M., Denèfle, P., Staels, B., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118687 · Cited by 251
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Seo, Y., Choi, I. S., & Shin, E. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.052 · Cited by 199
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia
Guérin, M., Bruckert, É., Dolphin, P. J., Turpin, G., & Chapman, M. J. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.6.763 · Cited by 195
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia
Koh, K. K., Han, S. H., Quon, M. J., Ahn, J. Y., & Shin, E. K. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1419 · Cited by 182
Beyond Low-Density Lipoprotein
Nesto, R. W. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505060-00005 · Cited by 176
Long-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined Hyperlipidemia
Ellen, R., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 175
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
Farnier, M., Freeman, M. W., Macdonell, G., Perevozskaya, I. T., Davies, M. J., Mitchel, Y., & Gumbiner, B. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi231 · Cited by 164
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–α Activators
Zambon, A., Gervois, P. P., Pauletto, P., Fruchart, J., & Staels, B. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000204327.96431.9a · Cited by 162
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial — FAT)
Malík, J. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00382-0 · Cited by 149
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
Vega, G. L., Ma, P. T. S., Cater, N. B., Filipchuk, N. G., Meguro, S., García-García, A.-B., & Grundy, S. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00111-5 · Cited by 149
Mechanisms of the Triglyceride- and Cholesterol-Lowering Effect of Fenofibrate in Hyperlipidemic Type 2 Diabetic Patients
Forcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., & Beylot, M. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3486 · Cited by 148
Serum homocysteine increases after therapy with fenofibrate or bezafibrate
Dierkes, J., Westphal, S., & Luley, C. H. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02153-4 · Cited by 144
The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia
Muhlestein, J. B., May, H. T., Jensen, J. R., Horne, B. D., Lanman, R. B., Lavasani, F., Wolfert, R. L., Pearson, R. R., Yannicelli, H. D., & Anderson, J. L. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.009 · Cited by 140
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
Fruchart, J., & Duriez, P. (2006) · Drugs of today · doi:10.1358/dot.2006.42.1.963528 · Cited by 132
Gemfibrozil in the Treatment of Dyslipidemia
Tenkanen, L., Mänttäri, M., Kovanen, P. T., Virkkunen, H., & Manninen, V. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.743 · Cited by 129
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
Frost, R. J., Otto, C., Geiss, H. C., SCHWANDT, P., & Parhofer, K. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01270-4 · Cited by 128
Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles
Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125
Risk of adverse events with fibrates*
Alsheikh-Ali, A. A. A., Kuvin, J. T., & Karas, R. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.033 · Cited by 125
Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.
CASLAKE, M. J., Packard, C. J., Gaw, A., Murray, E. F., Griffin, B. A., Vallance, B. D., & Shepherd, J. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.5.702 · Cited by 124
Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor α Modulation
Duez, H., Lefebvre, B., Poulain, P., Pineda‐Torra, I., Percevault, F., Luc, G., Peters, J. M., Gonzalez, F. J., Gineste, R., Helleboid, S., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000154140.73570.00 · Cited by 120
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., Demattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., & Leff, T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41090-9 · Cited by 118
Micronised Fenofibrate
Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 114
Self-citation
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
Durrington, P. N., Tuomilehto, J. O., Hamann, A., Kallend, D. G., & Smith, K. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.012 · Cited by 111
Adequacy of Glycemic, Lipid, and Blood Pressure Management for Patients With Diabetes in a Managed Care Setting
Beaton, S. J., Nag, S. S., Gunter, M. J., Gleeson, J. M., Sajjan, S. S., & Alexander, C. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.694 · Cited by 108
Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia
McKenney, J. M., Farnier, M., Lo, K.-W., Bays, H. E., Perevozkaya, I., Carlson, G. L., Davies, M. J., Mitchel, Y., & Gumbiner, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.072 · Cited by 106
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
Martin, P. D., Dane, A. L., Schneck, D. W., & Warwick, M. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80089-9 · Cited by 103
Lipid-lowering drugs and homocysteine
de Lorgeril, M., Salen, P., Paillard, F., Lacan, P., & Richard, G. J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)77220-2 · Cited by 102
Effects of fenofibrate and gemfibrozil on plasma homocysteine
Westphal, S., Dierkes, J., & Luley, C. H. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05271-5 · Cited by 99
Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268044 · Cited by 97
Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.
Shepherd, J., CASLAKE, M. J., Lorimer, A. R., Vallance, B. D., & Packard, C. J. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.2.162 · Cited by 96
Attenuation of Progression of Insulin Resistance in Patients With Coronary Artery Disease by Bezafibrate
Tenenbaum, A., Fisman, E. Z., Boyko, V., Benderly, M., Tanné, D., Haim, M., Matas, Z., Motro, M., & Behar, S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.737 · Cited by 94
Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers
Pan, W., Gustavson, L. E., Achari, R., Rieser, M. J., Ye, X., Gutterman, C., & Wallin, B. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008874 · Cited by 91
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia
Undas, A., Celińska‐Löwenhoff, M., Domagała, T. B., Iwaniec, T., Dropiński, J., Löwenhoff, T., & Szczeklik, A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0067 · Cited by 90
Effects of Short-Term Fenofibrate Treatment on Circulating Markers of Inflammation and Hemostasis in Patients with Impaired Glucose Tolerance
Okopień, B., Krysiak, R. G., & Herman, Z. S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1615 · Cited by 88
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia
Farnier, M. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.4.441 · Cited by 87
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study
Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Georgoula, M., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75078 · Cited by 86
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome
Filippatos, T. D., Gazi, I. F., Liberopoulos, E. N., Athyros, V. G., Elisaf, M., Tselepis, A. D., & Kiortsis, D. N. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.07.010 · Cited by 84
Short-Term Triglyceride Lowering With Fenofibrate Improves Vasodilator Function in Subjects With Hypertriglyceridemia
Capell, W. H., DeSouza, C. A., Poirier, P., Bell, M. L., Stauffer, B. L., Weil, K. M., Hernandez, T. L., & Eckel, R. H. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000046230.02211.b4 · Cited by 84
Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus
Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X
Idzior−Waluś, B., Sieradzki, J., Rostworowski, W., Zdzienicka, A., Kawalec, E., Wójcik, J., Zarnecki, A. F., & Blane, G. F. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00734.x · Cited by 83
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81
Comparison of fluvastatin + fenofibrate combination therapyand fluvastatin monotherapy in the treatment of combined hyperlipidemia,type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial
Derosa, G., Cicero, A. F. G., Bertone, G., Piccinni, M. N., Ciccarelli, L., & Roggeri, D. P. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.10.008 · Cited by 81
Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor–Dependent Manner
Arakawa, R., Tamehiro, N., Nishimaki‐Mogami, T., Ueda, K., & Yokoyama, S. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000163844.07815.c4 · Cited by 79
Fenofibrate Effectively Reduces Remnants, and Small Dense LDL, and Increases HDL Particle Number in Hypertriglyceridemic Men — A Nuclear Magnetic Resonance Study
Ikewaki, K., Tohyama, J., Nakata, Y., Wakikawa, T., Kido, T., & Mochizuki, S. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.278 · Cited by 76
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
Davidson, M. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.145 · Cited by 76
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
Playford, D. A., Watts, G. F., Best, J. D., & Burke, V. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02847-3 · Cited by 75
Untitled work
(1999) · PubMed · Cited by 74
Micronised fenofibrate
Munoz, A., Guichard, J. P., & Reginault, P. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)05375-s · Cited by 73
Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation
Sauron, R. É., Wilkins, M. R., Jessent, V., Dubois, A., Maillot, C., & Weil, A. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44064 · Cited by 72
Effect of Micronized Fenofibrate and Losartan Combination on Uric Acid Metabolism in Hypertensive Patients with Hyperuricemia
Elisaf, M., Tsimichodimos, V., Bairaktari, E. T., & Siamopoulos, K. C. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199907000-00010 · Cited by 67
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis
Koh, K. K., Ahn, J. Y., Han, S. H., Jin, D., Kim, H. S., Lee, K. C., Shin, E. K., & Sakuma, I. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.033 · Cited by 66
Fenofibrate raises plasma homocysteine levels in the fasted and fed states
Bissonnette, R., Treacy, E. P., Rozen, R. R., Boucher, B., Cohn, J. S., & Genest, J. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00584-0 · Cited by 62
Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*
Kosoglou, T., Statkevich, P., Fruchart, J., Pember, L. J. C., Reyderman, L., Cutler, D. L., Guillaume, M., Maxwell, S. E., & Veltri, E. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125004277 · Cited by 61
Comparative Effects of Atorvastatin, Simvastatin, and Fenofibrate on Serum Homocysteine Levels in Patients with Primary Hyperlipidemia
Milionis, H. J., Papakostas, J. C., Kakafika, A. I., Chasiotis, G., Seferiadis, K., & Elisaf, M. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003255920 · Cited by 61
AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.
Jellinger, P. S., Ra, D., Ganda, O. P., Ae, M., Tt, N., Rodbard, H. W., Ja, S., Shepherd, & Da, S. (2000) · PubMed · Cited by 58
Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Kim, J., Lee, Y., & Shin, E. K. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1418 · Cited by 57
Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia
Farnier, M., & Dejager, S. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00606-2 · Cited by 56
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia
Kiortsis, D. N., Millionis, H., Bairaktari, E. T., & Elisaf, M. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000213 · Cited by 56
THE LONG-TERM EFFECTS OF THE LIPID-LOWERING AGENT FENOFIBRATE IN HYPERLIPIDEMIC HEART TRANSPLANT RECIPIENTS
Boissonnat, P., Salen, P., Guidollet, J., Ferreea, R., Dueeau, G., Ninet, J., Renaud, S., & de Lorgeril, M. (1994) · Transplantation · doi:10.1097/00007890-199405820-00018 · Cited by 55
Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values
Tsimihodimos, V., Kostoula, A., Kakafika, A. I., Bairaktari, E. T., Tselepis, A. D., Mikhailidis, D. P., & Elisaf, M. (2004) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840400900i105 · Cited by 55
Multicenter Comparison of Micronized Fenofibrate and Simvastatin in Patients with Primary Type IIA or IIB Hyperlipoproteinemia
Steinmetz, A., Schwartz, T., Hehnke, U., & Kaffarnik, H. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199604000-00016 · Cited by 54
Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome
Wysocki, J., Belowski, D., Kalina, M. A., Kochański, L., Okopień, B., & Kalina, Z. (2004) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp42212 · Cited by 52
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
McKenney, J. M., Jones, M., & Abby, S. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59157 · Cited by 51
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus
Genest, J., Frohlich, J., & Steiner, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.12.022 · Cited by 51
Effect of Micronized Fenofibrate on Plasma Lipoprotein Levels and Hemostatic Parameters of Hypertriglyceridemic Patients with Low Levels of High-Density Lipoprotein Cholesterol in the Fed and Fasted State
Genest, J. J., Nh, N., Théroux, P., Davignon, J., & Cohn, J. S. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200001000-00022 · Cited by 49
Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Robins, S. J. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200312000-00005 · Cited by 47
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial
Després, J., Lemieux, I., Salomon, H., & Delaval, D. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00988.x · Cited by 44
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)
Farnier, M., Salko, T., Isaacsohn, J. L., Troendle, A. J., Dejager, S., & Gonasun, L. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00885-3 · Cited by 41
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients
Lemieux, I., Salomon, H., & Després, J. (2003) · Annals of Medicine · doi:10.1080/07853890310011969 · Cited by 40
After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
Colhoun, H. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67668-4 · Cited by 39
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease
Paragh, G., Seres, I., Harangi, M., Balogh, Z., Illyés, L., Boda, J., Szilvássy, Z., & Kovacs, P. L. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70077-0 · Cited by 39
Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgian multicenter study
Kornitzer, M., Dramaix, M. W., Vandenbroek, M.-D., Everaert, L., & Gerlinger, C. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)05378-v · Cited by 39
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide
Kajosaari, L. I., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02158.x · Cited by 37
Fenofibrate or Gemfibrozil for Treatment of Types IIa and IIb Primary Hyperlipoproteinemia: A Randomized, Double-Blind, Crossover Study
Insua, A., Massari, F., Moncalvo, J. J. R., Zanchetta, J., & Insua, A. M. (2002) · Endocrine Practice · doi:10.4158/ep.8.2.96 · Cited by 36
Fenofibrate Monotherapy Induced Rhabdomyolysis
Barker, B. J., Goodenough, R. R., & Falko, J. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2482 · Cited by 36
Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart Disease
Packard, K. A., Backes, J. M., Lenz, T. L., Wurdeman, R. L., Destache, C. J., & Hilleman, D. E. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.17.1527.34128 · Cited by 35
Monocyte suppressing action of fenofibrate.
Okopień, B., Kowalski, J., Krysiak, R. G., Łabuzek, K., Stachura-Kułach, A., Kułach, A., Zieliński, M., & Herman, Z. S. (2005) · PubMed · Cited by 34
Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study
Sasaki, J. D., Yamamoto, K., & Ageta, M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80064-9 · Cited by 34
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome
Watts, G. F., Ji, J., Chan, D. C., Ooi, E. M. M., Johnson, A. G., Rye, K., & Barrett, P. H. R. (2006) · Clinical Science · doi:10.1042/cs20060072 · Cited by 34
Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia
Kowalski, J., Okopień, B., Madej, A., Zieliński, M., Belowski, D., Kalina, Z., & Herman, Z. S. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41241 · Cited by 34
A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism
Kürşat, S., Alici, T., & Çolak, H. (2005) · Clinical Nephrology · doi:10.5414/cnp64391 · Cited by 33
Effects of fibrates on plasma prothrombotic activity in patients with Type IIb dyslipidemia
Okopień, B., Cwalina, L., Lebek, M., Kowalski, J., Zieliński, M., Wisniewska-Wanat, M., Kalina, Z., & Herman, Z. S. (2001) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp39551 · Cited by 32
Review: Fibrates: therapeutic review
Chapman, M. J. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060010201 · Cited by 31
Effect of Monthly Atorvastatin and Fenofibrate Treatment on Monocyte Chemoattractant Protein-1 Release in Patients with Primary Mixed Dyslipidemia
Okopień, B., Krysiak, R. G., Haberka, M., & Herman, Z. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000156821.50457.32 · Cited by 29
Effect of Colesevelam HCl on Single-Dose Fenofibrate Pharmacokinetics
Jones, M., Baker, B., & Mathew, P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00006 · Cited by 29
Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
Krempf, M., Rohmer, V., Farnier, M., Issa-Sayegh, M., Corda, C., Sirugue, I., Gerlinger, C., & Masseyeff-Elbaz, M. F. (2000) · PubMed · Cited by 28
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia
Saklamaz, A., Çömlekçi, A., Artmann, A. T., Uysal, S., Ceylan, C., Alacacıoğlu, A., & Yeşil, S. (2005) · Metabolism · doi:10.1016/j.metabol.2004.12.012 · Cited by 28
Untitled work
(2000) · PubMed · Cited by 28
Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative
Farnier, M. (2003) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200303030-00003 · Cited by 27
The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3α‐Hydroxy Isomeric Metabolite
Gustavson, L. E., Schweitzer, S. M., Koehne‐Voss, S., Achari, R., Chira, T. O., Esslinger, H., & Yannicelli, H. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278085 · Cited by 27
Rhabdomyolysis with Cardiac Involvement and Acute Renal Failure in a Patient Taking Rosuvastatin and Fenofibrate
Ireland, J. H. E., Eggert, C. H., Arendt, C. J., & Williams, A. W. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-11-200506070-00020 · Cited by 26
Qualitative Effect of Fenofibrate and Quantitative Effect of Atorvastatin on LDL Profile in Combined Hyperlipidemia with dense LDL
Winkler, K. E., Weltzien, P., Friedrich, I., Schmitz, H., Nickell, H.-H., Hauck, P., Hoffmann, M. M., Baumstark, M. W., Wieland, H., & März, W. (2004) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-817970 · Cited by 25
Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control
Tan, C., Chew, L. S., Tai, E. S., Chio, L. F., Lim, H., Loh, L. M., & Shepherd, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00497-4 · Cited by 25
Role of Lp A-I and Lp A-I/A-II in Cholesteryl Ester Transfer Protein–Mediated Neutral Lipid Transfer
McPherson, R., Agnani, G., Lau, P., Fruchart, J., Edgar, A. D., & Marcel, Y. L. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.11.1340 · Cited by 25
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia
Kowalski, J., Belowski, D., Okopień, B., Madej, A., Zieliński, M., Kalina, Z., & Herman, Z. S. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0581-7 · Cited by 25
Effectiveness and Tolerability of 12-Week Treatment with Micronised Fenofibrate 200mg in a Drug-Monitoring Programme Involving 9884 Patients with Dyslipidaemia
ssler, K. U. K., Schmitz, H., & Bach, G. (1998) · Clinical Drug Investigation · doi:10.2165/00044011-199815030-00004 · Cited by 25
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects
Gustavson, L. E., Schweitzer, S. M., Burt, D. A., Achari, R., Rieser, M. J., Edeki, T. I., Chira, T. O., Yannicelli, H. D., & Kelly, M. T. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.03.009 · Cited by 23
Normalization of metabolic syndrome using fenofibrate, metformin or their combination
Nieuwdorp, M., Stroes, E. S. G., Kastelein, J. J. P., & Fenofibrate/Metformin study group (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00668.x · Cited by 23
Fenofibrate improves microcirculation in patients with hyperlipidemia.
Haak, T., Haak, E., Kusterer, K., Weber, A., Kohleisen, M., & Usadel, K.-H. (1998) · PubMed · Cited by 23
The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Yeşilbursa, D., Serdar, A., Saltan, Y., Serdar, Z., Heper, Y., Güçlü, S., & Cordan, J. (2005) · PubMed · Cited by 22
Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia
Ye, P., Li, J., Su, G., & Zhang, C. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.01.023 · Cited by 21
The Role of Fibrates in a Statin World
Bloomfield, H. E. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.715 · Cited by 21
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone
Ledl, M., Hohenecker, J., Francesconi, C. M., Roots, I., Bauer, M. F., & Roden, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1919-8 · Cited by 21
Simvastatin, Fenofibrate, and Rhabdomyolysis
Jacob, S. S., Jacob, S., Williams, C. D., & Deeg, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1258 · Cited by 20
Efficacy and tolerability of a “suprabioavailable” formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials
Ramjattan, B., Callaghan, D. J. G., & Theiss, U. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80022-4 · Cited by 18
Effect of Fenofibrate on Lipoprotein(a) in Hypertriglyceridemic Patients
Ko, H. S., Kim, C. J., & Ryu, W. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000175875.48167.c7 · Cited by 18
Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia
Yang, T., Chen, M., Xia, X., Bai-lin, L., & Li, Y. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0095-6 · Cited by 18
Combined Treatment with Fibrates and Small Doses of Atorvastatin in Patients with Mixed Hyperlipidemia
Liamis, G. L., Kakafika, A. I., Bairaktari, E. T., Miltiadous, G. A., Tsimihodimos, V., Goudevenos, J. A., Achimastos, A. D., & Elisaf, M. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000372 · Cited by 18
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients
Çoban, E., Özdoğan, M., Yazicioglu, G., & Sarı, R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00428.x · Cited by 17
Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia
Rašlová, K., Dubovská, D., Mongiellová, V., & Trnovec, T. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050257 · Cited by 17
Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control
Cavallero, E., Dachet, C., Assadollahi, F., Martin, C., Navarro, N., Ansquer, J.-C., Corda, C., Foucher, C., Juhan-Vague, I., & JACOTOT, B. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00321-0 · Cited by 17
Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb
Bertolini, S., Elicio, N., Daga, A., Degl’Innocenti, M. L., Balestreri, R., Fusi, M. G., Ramusino, A. M. C., & Carozzi, A. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf01061412 · Cited by 15
Comparison of Micronized Fenofibrate and Pravastatin in Patients With Primary Hyperlipidemia
Ducobu, J., Vanhaelst, L., & Salomon, H. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200301000-00008 · Cited by 13
Efficacy, Safety and Tolerability of???Combined Low-Dose Simvastatin-Fenofibrate Treatment in Primary Mixed Hyperlipidaemia
Stefanutti, C., Bucci, A., Giacomo, S. D., Fraone, N., Pace, A., Mareri, M., Musca, A., & Mammarella, A. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424080-00005 · Cited by 13
Management of Diabetic Dyslipidemia
Khera, A., & McGuire, D. K. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505020-00002 · Cited by 12
Effect of Fenofibrate on Uric Acid Metabolism in Japanese Hyperlipidemic Patients
Noguchi, Y., Tatsuno, I., Suyama, K., Shibata, T., Yoshida, T., Otsuka, Y., Fuse, M., Takeo, C., & Saitō, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.335 · Cited by 12
Fenofibrate-induced myopathy.
Ghosh, B., Sengupta, S., Bhattacharjee, B., Majumder, A., & Sarkar, S. B. (2004) · PubMed · Cited by 11
A New Perspective in the Treatment of Dyslipidemia
Steiner, G. A. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504050-00004 · Cited by 10
A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Zhu, J., & Ye, P. (2003) · PubMed · Cited by 5
Untitled work
Laffel (1999) · doi:10.1002/(sici)1520-7560(199911/12)15:6

Research works printed but not linked: 9

Haak, 1998, Eur J Med Res, 3, 50
Krempf, 2000, Diabetes Metab, 26, 184
Yesilbursa, 2005, Kardiol Pol, 62, 526
Pfutzner, 1994, Z Allg Med, 70, 510
Marz, 1994, Munch Med Wochenschr, 136, 690
Zhu, 2003, Chin Med J, 116, 840
Farnier, 1994, Arch Intern Med, 154, 441, 10.1001/archinte.1994.00420040119015 · DOI
Levin, 2000, Clin Nephrol, 53, 140
Ghosh, 2004, Neurol India, 52, 268

Sorted by citations

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC
Tsume, Y., Mudie, D. M., Langguth, P., Amidon, G. E., & Amidon, G. L. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.01.009 · Cited by 375
Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with Captopril
Susalit, E., Agus, N., Effendi, I., Tjandrawinata, R. R., Nofiarny, D., Perrinjaquet-Moccetti, T., & Verbruggen, M. A. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.08.016 · Cited by 247
Room‐Temperature Decarboxylative Alkynylation of Carboxylic Acids Using Photoredox Catalysis and EBX Reagents
Vaillant, F. L., Courant, T., & Waser, J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505111 · Cited by 224
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270

See all 169

Authors: Keating, G. M., & Croom, K. F.
Affiliations: Wolters Kluwer Health (NZ)
Corresponding author: Keating, Gillian M
Venue: Drugs
Publisher: Springer Science and Business Media LLC
Published: 2007
Volume: 67
Issue: 1
Pages: 121-153
ISSN: 0012-6667 (ISSN-L)
DOI: 10.2165/00003495-200767010-00013
OpenAlex: W2005965794
Cited by: 169
References: 173
Citations by year: 2026: 3 · 2025: 13 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 9 · 2014: 8 · 2013: 10 · 2012: 9
FWCI: 3.08
Type: journal article
Language: en
Open access: closed
Locations: Drugs (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords: fenofibrate, fibrates, PPARα, primary hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia, atherogenic dyslipidemia, metabolic syndrome, type 2 diabetes, statin combination therapy, ezetimibe, cardiovascular risk reduction, primary prevention, rhabdomyolysis
MeSH terms: Hypolipidemic Agents, Diabetes Mellitus, Type 2, Humans, Fenofibrate, Metabolic Syndrome, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks